Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Zeen Tong, Allison Gaudy, Daniel Tatosian, Francisco Ramirez-Valle, Hong Liu, Jian Chen, Matthew Hoffmann & Sekhar Surapaneni. (2021) Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase. Xenobiotica 51:12, pages 1416-1426.
Read now
Read now
Jiaqi Li, Liuying Di, Xu Cheng, Weiwen Ji, Hongyu Piao, Gang Cheng & Meijuan Zou. (2020) The characteristics and mechanism of co-administration of lovastatin solid dispersion with kaempferol to increase oral bioavailability. Xenobiotica 50:5, pages 593-601.
Read now
Read now
Pritesh Kumar, Carl A. Carrasquer, Arren Carter, Zhao-Hui Song & Albert R. Cunningham. (2014) A categorical structure–activity relationship analysis of GPR119 ligands. SAR and QSAR in Environmental Research 25:11, pages 891-903.
Read now
Read now
. (2014) ABSTRACTS FROM THE 10TH INTERNATIONAL ISSX MEETING. Drug Metabolism Reviews 45:sup1, pages 1-286.
Read now
Read now
Articles from other publishers (35)
Priyanshu Nema, Vivek Asati, Priyadarshi Kendya, Twinkle Gupta, Shivangi Agarwal, Shivam Kori, Varsha Kashaw, Arun K. Iyer & Sushil Kumar Kashaw. (2023) Structural Insight on GPR119 Agonist as Potential Therapy for Type II
Diabetes: A Comprehensive Review. Mini-Reviews in Medicinal Chemistry 23:21, pages 2008-2040.
Crossref
Crossref
Yiming Cheng, Xiaomin Wang, Zeen Tong, Josephine Reyes, Leon Carayannopoulos, Simon Zhou & Yan Li. (2021) Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The Journal of Clinical Pharmacology 62:4, pages 494-504.
Crossref
Crossref
Dorien Groenendaal‐van de Meent, Martin den Adel, Virginie Kerbusch, Jan Dijk, Tomohisa Shibata, Kota Kato & Marloes Schaddelee. (2022) Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open‐Label, 1‐Sequence, Crossover Studies. Clinical Pharmacology in Drug Development 11:4, pages 486-501.
Crossref
Crossref
Ajay Manaithiya, Ozair Alam, Vrinda Sharma, Mohd. Javed Naim, Shruti Mittal & Imran A Khan. (2021) GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus. Bioorganic Chemistry 113, pages 104998.
Crossref
Crossref
Xiaoshu Dai, Michael D. Karol, Matthew Hitron, Marjie L. Hard, Matthew T. Goulet, Colleen F. McLaughlin & Scott J. Brantley. (2021) Napabucasin Drug‐Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers. Clinical Pharmacology in Drug Development.
Crossref
Crossref
Dénes Csonka, Shirin Bruderer, Armin Schultz, Marianne Soergel, Radka Stepanova, Giancarlo Sabattini & Juan Jose Perez-Ruixo. (2019) Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects. Clinical Drug Investigation 39:12, pages 1223-1232.
Crossref
Crossref
Edyta Gendaszewska-Darmach, Anna Drzazga & Maria Koziołkiewicz. (2019) Targeting GPCRs Activated by Fatty Acid-Derived Lipids in Type 2 Diabetes. Trends in Molecular Medicine 25:10, pages 915-929.
Crossref
Crossref
Birk Poller, Ralph Woessner, Avantika Barve, Hanns-Christian Tillmann, Janardhana Vemula, Alexandra Nica, Walid Elbast, Hilmar Schiller, Peter End, Gian Camenisch & Markus Weiss. (2019) Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Pulmonary Pharmacology & Therapeutics 57, pages 101809.
Crossref
Crossref
Aman Chandra Kaushik, Ajay Kumar, Ashfaq Ur Rehman, Muhammad Junaid, Abbas Khan, Shiv Bharadwaj, Shakti Sahi & Dong-Qing Wei. (2018) Deciphering G-Protein-Coupled Receptor 119 Agonists as Promising Strategy against Type 2 Diabetes Using Systems Biology Approach. ACS Omega 3:12, pages 18214-18226.
Crossref
Crossref
Daisuke Matsuda, Madoka Kawamura, Yohei Kobashi, Fumiyasu Shiozawa, Youichirou Suga, Keiko Fusegi, Shinichi Nishimoto, Kayo Kimura, Masako Miyoshi, Noriko Takayama, Hiroyuki Kakinuma & Norikazu Ohtake. (2018) Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists. Bioorganic & Medicinal Chemistry 26:8, pages 1832-1847.
Crossref
Crossref
Jin Won Yang, Hyo Seon Kim, Yong‐Won Choi, Young‐Mi Kim & Keon Wook Kang. (2017)
Therapeutic application of
GPR119
ligands in metabolic disorders
. Diabetes, Obesity and Metabolism 20:2, pages 257-269.
Crossref
Crossref
Hyojin Kim, Suk Joon Cho, Minjin Yoo, Seung Kyu Kang, Kwang Rok Kim, Hwan Hee Lee, Jin Sook Song, Sang Dal Rhee, Won Hoon Jung, Jin Hee Ahn, Jae-Kyung Jung & Kwan-Young Jung. (2017) Synthesis and biological evaluation of thiazole derivatives as GPR119 agonists. Bioorganic & Medicinal Chemistry Letters 27:23, pages 5213-5220.
Crossref
Crossref
Jeffrey E. Edwards, Lise Eliot, Andrew Parkinson, Sharon Karan & Leigh MacConell. (2017) Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Advances in Therapy 34:9, pages 2120-2138.
Crossref
Crossref
Yoon Kyung Jang, Kyu Myung Lee, Kwan-Young Jung, Seung Kyu Kang, Suvarna H. Pagire, Jun Mi Lee, Haushabhau S. Pagire, Kwang Rok Kim, Myung Ae Bae, Hohjai Lee, Sang Dal Rhee & Jin Hee Ahn. (2017) Design, synthesis, and biological evaluation of aryl N-methoxyamide derivatives as GPR119 agonists. Bioorganic & Medicinal Chemistry Letters 27:16, pages 3909-3914.
Crossref
Crossref
Daisuke Matsuda, Yohei Kobashi, Ayako Mikami, Madoka Kawamura, Fumiyasu Shiozawa, Kenichi Kawabe, Makoto Hamada, Shinichi Nishimoto, Kayo Kimura, Masako Miyoshi, Noriko Takayama, Hiroyuki Kakinuma & Norikazu Ohtake. (2017) Novel 3 H -[1,2,3]triazolo[4,5- c ]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity/solubility relationships. Bioorganic & Medicinal Chemistry 25:16, pages 4339-4354.
Crossref
Crossref
Ayman F. El‐Kattan. 2017. Oral Bioavailability Assessment. Oral Bioavailability Assessment
203
267
.
Zunhua Yang, Yuanying Fang & Haeil Park. (2017) Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist. Bioorganic & Medicinal Chemistry Letters 27:11, pages 2515-2519.
Crossref
Crossref
Suhong Fu, Wei Xiang, Jinying Chen, Liang Ma & Lijuan Chen. (2017) Synthesis and biological evaluation of 1, 2, 4-oxadiazole derivatives as novel GPR119 agonists. Chemical Biology & Drug Design 89:5, pages 815-819.
Crossref
Crossref
Cheng Zhu, Liping Wang, Yuping Zhu, Zack Zhiqiang Guo, Ping Liu, Zhiyong Hu, Jason W. Szewczyk, Ling Kang, Gary Chicchi, Anka Ehrhardt, Andrea Woods, Toru Seo, Morgan Woods, Margaret van Heek, Karen H. Dingley, Jianmei Pang, Gino M. Salituro, Joyce Powell, Jenna L. Terebetski, Viktor Hornak, Louis-Charles Campeau, Robert K. Orr, Feroze Ujjainwalla, Michael Miller, Andrew Stamford, Harold B. Wood, Timothy Kowalski, Ravi P. Nargund & Scott D. Edmondson. (2017) Discovery of phenyl acetamides as potent and selective GPR119 agonists. Bioorganic & Medicinal Chemistry Letters 27:5, pages 1124-1128.
Crossref
Crossref
Brian M Moran, Aine M McKillop & Finbarr PM O’Harte. (2016) Development of novel ligands for peptide GPCRs. Current Opinion in Pharmacology 31, pages 57-62.
Crossref
Crossref
Daisuke Matsuda, Yohei Kobashi, Ayako Mikami, Madoka Kawamura, Fumiyasu Shiozawa, Kenichi Kawabe, Makoto Hamada, Koji Oda, Shinichi Nishimoto, Kayo Kimura, Masako Miyoshi, Noriko Takayama, Hiroyuki Kakinuma & Norikazu Ohtake. (2016) Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists. Bioorganic & Medicinal Chemistry Letters 26:15, pages 3441-3446.
Crossref
Crossref
Kurt Ritter, Christian Buning, Nis Halland, Christoph Pöverlein & Lothar Schwink. (2015) G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges. Journal of Medicinal Chemistry 59:8, pages 3579-3592.
Crossref
Crossref
Brian M. Moran, Peter R. Flatt & Aine M. McKillop. (2016) G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis. Acta Diabetologica 53:2, pages 177-188.
Crossref
Crossref
C.E. Herron, C.C. Brueckner, J.P. Chism, D.C. Kemp, J.S. Prescott, G.A. Smith, D.H. Melich, N. Oleas & J.W. Polli. (2015) Toxicokinetics and toxicity of atorvastatin in dogs. Toxicology and Applied Pharmacology 289:1, pages 117-123.
Crossref
Crossref
Ping Liu, Zhiyong Hu, Byron G. DuBois, Christopher R. Moyes, David N. Hunter, Cheng Zhu, Nam Fung Kar, Yuping Zhu, Joie Garfunkle, Ling Kang, Gary Chicchi, Anka Ehrhardt, Andrea Woods, Toru Seo, Morgan Woods, Margaret van Heek, Karen H. Dingley, Jianmei Pang, Gino M. Salituro, Joyce Powell, Jenna L. Terebetski, Viktor Hornak, Louis-Charles Campeau, Joe Lamberson, Fez Ujjainwalla, Michael Miller, Andrew Stamford, Harold B. Wood, Timothy Kowalski, Ravi P. Nargund & Scott D. Edmondson. (2015) Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes. ACS Medicinal Chemistry Letters 6:8, pages 936-941.
Crossref
Crossref
Nikolaos Tsamandouras, Gemma Dickinson, Yingying Guo, Stephen Hall, Amin Rostami-Hodjegan, Aleksandra Galetin & Leon Aarons. (2014) Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. Pharmaceutical Research 32:6, pages 1864-1883.
Crossref
Crossref
Jerome Hochman, Cuyue Tang & Thomayant Prueksaritanont. (2015) Drug–Drug Interactions Related to Altered Absorption and Plasma Protein Binding: Theoretical and Regulatory Considerations, and an Industry Perspective. Journal of Pharmaceutical Sciences 104:3, pages 916-929.
Crossref
Crossref
Qingcheng Mao & Jashvant D. Unadkat. (2014) Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update. The AAPS Journal 17:1, pages 65-82.
Crossref
Crossref
James S. ScottSuzanne S. BowkerKaty J. BrocklehurstHayley S. BrownDavid S. ClarkeAlison EasterAnne Ertan, Kristin GoldbergJulian A. HudsonStefan KavanaghDavid LaberAndrew G. LeachPhilip A. MacFaulElizabeth A. MartinDarren McKerrecherPaul SchofieldPer H. Svensson & Joanne Teague. (2014) Circumventing Seizure Activity in a Series of G Protein Coupled Receptor 119 (GPR119) Agonists. Journal of Medicinal Chemistry 57:21, pages 8984-8998.
Crossref
Crossref
Sarah K. Lawrence, Dung Nguyen, Chet Bowen, Lauren Richards-Peterson & Konstantine W. Skordos. (2014) The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk. Drug Metabolism and Disposition 42:7, pages 1180-1190.
Crossref
Crossref
Derek J. Nunez, Mark A. Bush, David A. Collins, Susan L. McMullen, Dawn Gillmor, Glen Apseloff, George Atiee, Leonor Corsino, Linda Morrow & Paul L. Feldman. (2014) Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies. PLoS ONE 9:4, pages e92494.
Crossref
Crossref
Paul Gillespie, Robert A. GoodnowJr.Jr., Goutam Saha, Gopal Bose, Kakali Moulik, Catherine Zwingelstein, Michael Myers, Karin Conde-Knape, Sherrie Pietranico-Cole & Sung-Sau So. (2014) Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists. Bioorganic & Medicinal Chemistry Letters 24:3, pages 949-953.
Crossref
Crossref
Xiu-Lei Mo, Zhao Yang & Ya-Xiong Tao. 2014. Glucose Homeostatis and the Pathogenesis of Diabetes Mellitus. Glucose Homeostatis and the Pathogenesis of Diabetes Mellitus
95
131
.
Carole E. Shardlow, Grant T. Generaux, Aarti H. Patel, Guoying Tai, Thuy Tran & Jackie C. Bloomer. (2013) Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development. Drug Metabolism and Disposition 41:12, pages 1994-2003.
Crossref
Crossref
Melinda J. Reese, Paul M. Savina, Grant T. Generaux, Helen Tracey, Joan E. Humphreys, Eri Kanaoka, Lindsey O. Webster, Kelly A. Harmon, James D. Clarke & Joseph W. Polli. (2013) In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor. Drug Metabolism and Disposition 41:2, pages 353-361.
Crossref
Crossref